Figure 1.

(A) PFS in the ITT population and (B) a forest plot summary of PFS HRs in subgroups by prior lines, prior therapies, treatment-free intervals. Kaplan- Meier analysis of PFS among patients in the ITT population. ^aTreatment-free interval was defined as the duration between the end date of the last line of prior therapy and randomization. ^bHigh-risk patients had any of t(4;14), t(14;16), or del17p as assessed by next generation sequencing. ^cStandard-risk patients had an absence of highrisk abnormalities. PFS: progression- free survival; ITT: intenttotreat; HR: hazard ratio; D-Rd: daratumumab/lenalidomide/dex amethasone; Rd: lenalidomide/dexamethasone; CI: confidence interval; NR: not reached; TFI: treatment-free interval; std: standard.